Preventive treatment of migraine headache with a new isoergolenyl derivative.
In the present double-blind clinical trial an isoergolenyl derivative with periphal antiserotonin, central dopaminergic activity and alpha-increasing effect on the human EEG, lisuride hydrogen maleate, was tested against placebo in a six-month trial involving 240 patients. Lisuride in long-term administration significantly reduces the frequency of migraine attacks in comparison to placebo. Its advantages are good tolerance and minimal side-effects. It is therefore concluded that lisuride is a suitable and effective drug for the prevention of migraine.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D008090:Lisuride / Q000009:adverse effects / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000517:prevention & control*; D010919:Placebos
D004873:Ergolines; D010919:Placebos; D008090:Lisuride